Regenxbio Inc

자세한 내용은 Regenxbio Inc 회사

REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.

회사 정보

종목 코드 RGNX

회사 이름Regenxbio Inc

상장일Sep 17, 2015

CEOMr. Curran M. Simpson

직원 수353

유형Ordinary Share

회계 연도 종료Sep 17

주소9804 Medical Center Drive

도시ROCKVILLE

증권 거래소NASDAQ Global Select Consolidated

국가United States of America

우편 번호20850

전화12405528181

웹사이트https://regenxbio.com/

종목 코드 RGNX

상장일Sep 17, 2015

CEOMr. Curran M. Simpson

회사 임원

이름

이름/직위

직위

주식 보유

변동

Mr. Mitchell Chan

Chief Financial Officer, Executive Vice President, Principal Accounting Officer

58.87K

--

Dr. Olivier Danos, Ph.D.

Executive Vice President, Chief Scientific Officer

58.37K

-55.17%

Mr. Curran M. Simpson

President, Chief Executive Officer, Director

31.47K

-13.00%

Ms. Jennifer L. Zachary

Independent Director

20.06K

+63.21%

Mr. Daniel Tasse

Lead Independent Director

19.05K

+68.83%

Mr. George V. Migausky

Independent Director

19.05K

+68.83%

Mr. Craig Malzahn

Executive Vice President - Product Development, Chief Technology Officer

17.82K

--

Mr. Allan M. Fox, J.D.

Director

--

Dr. David C. (Dave) Stump, M.D.

Independent Director

--

Dr. A. N. (Jerry) Karabelas, Ph.D.

Independent Director

--

이름

이름/직위

직위

주식 보유

변동

Mr. Mitchell Chan

Chief Financial Officer, Executive Vice President, Principal Accounting Officer

58.87K

--

Dr. Olivier Danos, Ph.D.

Executive Vice President, Chief Scientific Officer

58.37K

-55.17%

Mr. Curran M. Simpson

President, Chief Executive Officer, Director

31.47K

-13.00%

Ms. Jennifer L. Zachary

Independent Director

20.06K

+63.21%

Mr. Daniel Tasse

Lead Independent Director

19.05K

+68.83%

Mr. George V. Migausky

Independent Director

19.05K

+68.83%

수익 분석

데이터 없음

데이터 없음

사업별

지역별

데이터 없음

주식 보유 통계

마지막 업데이트: Sat, May 17

주주

주주 유형

주주

비율

Redmile Group, LLC

9.52%

BlackRock Institutional Trust Company, N.A.

7.77%

The Vanguard Group, Inc.

6.89%

JP Morgan Asset Management

5.85%

Fox (Allan Mark)

5.76%

Other

64.21%

주주

비율

Redmile Group, LLC

9.52%

BlackRock Institutional Trust Company, N.A.

7.77%

The Vanguard Group, Inc.

6.89%

JP Morgan Asset Management

5.85%

Fox (Allan Mark)

5.76%

Other

64.21%

주주 유형

주주

비율

Investment Advisor/Hedge Fund

29.45%

Investment Advisor

29.40%

Hedge Fund

17.30%

Research Firm

8.25%

Individual Investor

7.69%

Sovereign Wealth Fund

2.96%

Pension Fund

0.32%

Bank and Trust

0.25%

Family Office

0.10%

Other

4.27%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

421

48.24M

95.74%

-3.52M

2025Q1

446

48.46M

96.35%

-3.90M

2024Q4

444

48.16M

97.22%

-4.82M

2024Q3

444

49.64M

100.43%

-4.45M

2024Q2

437

49.30M

99.98%

-3.20M

2024Q1

451

48.23M

99.21%

+414.63K

2023Q4

436

43.62M

98.84%

-7.14M

2023Q3

439

43.73M

99.56%

-6.26M

2023Q2

439

43.86M

100.57%

-5.31M

2023Q1

456

44.07M

101.46%

-1.49M

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

Redmile Group, LLC

4.79M

9.52%

--

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

3.92M

7.77%

+48.66K

+1.26%

Mar 31, 2025

The Vanguard Group, Inc.

3.47M

6.89%

+495.83K

+16.65%

Mar 31, 2025

JP Morgan Asset Management

2.95M

5.85%

+36.88K

+1.27%

Mar 31, 2025

Fox (Allan Mark)

2.90M

5.76%

+7.77K

+0.27%

May 30, 2025

Morgan Stanley & Co. LLC

1.57M

3.11%

+45.10K

+2.96%

Mar 31, 2025

Balyasny Asset Management LP

1.40M

2.78%

+211.40K

+17.81%

Mar 31, 2025

Dimensional Fund Advisors, L.P.

1.15M

2.28%

-23.70K

-2.02%

Mar 31, 2025

Geode Capital Management, L.L.C.

1.11M

2.2%

+12.72K

+1.16%

Mar 31, 2025

BlackRock Financial Management, Inc.

1.09M

2.17%

-19.59K

-1.76%

Mar 31, 2025

8.372USD

Regenxbio Inc

8.372

개요

회사

금융